Vanda Pharmaceuticals(US:VNDA) 美股IPO·2026-01-01 04:13Core Viewpoint - Vanda Pharmaceuticals (VNDA.US) stock price increased by over 25.46% following the FDA approval of its new drug Nereus, which is intended for the prevention of vomiting induced by motion [1][2]. Group 1: FDA Approval and Drug Details - The FDA approval of Nereus is based on results from three clinical studies that compared the drug group with a placebo group to assess the occurrence of vomiting [2]. - Data from the trials indicated that Nereus achieved a "significant reduction" in vomiting events and demonstrated "good safety characteristics" in short-term, acute use scenarios [2]. Group 2: Market Implications - The approval of Nereus is expected to provide a new commercialization growth point for the company and further enrich its product portfolio in the central nervous system and related indications [2].